VANDA PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M | $55.6M | $48.6M | $43.6M |
| SG&A Expense | $238.0M | $146.4M | $112.9M | $136.5M | $124.0M | $140.5M | $129.7M | $105.8M |
| Operating Income | $-151.2M | $-40.7M | $-14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M |
| Operating Margin | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% | 11.0% | 10.0% | 11.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-138.6M | $-22.9M | $6.3M | $11.3M | $42.4M | $31.7M | $29.0M | $25.3M |
| Income Tax Expense | $81.8M | $-4.0M | $3.8M | $5.0M | $9.2M | $8.3M | $-86.5M | $138.0K |
| Net Income | $-220.5M | $-18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M |
| Net Margin | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% |
| EPS (Basic) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.60 | $0.43 | $2.17 | $0.50 |
| EPS (Diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 |
| Shares Outstanding (Basic) | 58.9M | 58.1M | 57.4M | 56.5M | 55.5M | 54.4M | 53.1M | 50.9M |
| Shares Outstanding (Diluted) | 58.9M | 58.1M | 57.6M | 57.0M | 56.9M | 55.2M | 54.8M | 53.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |